Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 15/20 | 0.41 |
| ▸ | ACACA | Q13085 | 15/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | USP28 | Q96RU2 | 2/20 | 0.31 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3490888 | 1.00 | ACACB (0.41) | ACACBACACAMAPTHTTUSP28 | |
| SCHEMBL3492147 | 0.92 | ACACB (0.41) | ACACBACACAMAPT | |
| SCHEMBL3492142 | 0.92 | ACACB (0.41) | ACACBACACAMAPT | |
| SCHEMBL3491829 | 0.91 | ACACB (0.41) | ACACBACACAMAPTUSP28USP25 | |
| SCHEMBL3491825 | 0.91 | ACACB (0.41) | ACACBACACAMAPTUSP28USP25 | |
| SCHEMBL3495471 | 0.89 | ACACB (0.51) | ACACBACACA | |
| SCHEMBL3495469 | 0.89 | ACACB (0.51) | ACACBACACA | |
| SCHEMBL3494893 | 0.89 | ACACB (0.40) | ACACBACACAMAPTKDM4EHSD17B10 | |
| SCHEMBL3494892 | 0.89 | ACACB (0.40) | ACACBACACAMAPTKDM4EHSD17B10 | |
| SCHEMBL3494509 | 0.89 | ACACB (0.42) | ACACBACACAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123652-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
| EP-2123652-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | ACACA, ACAT1, CPT1B | ACACB 5/4885ACACA 1/4885MAPT 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.